| Randy Perrin |
Randy Perrin is a member of the Medical Affairs Professional Society and the Medical Science Liaison Society, Inc. He is also the GVP-Global Medical Affairs at Kiniksa Pharmaceuticals Ltd. Mr. Perrin has an undergraduate degree from the University of Michigan, a doctorate from Walden University LLC, and another undergraduate degree from Indiana State University. |
| Eben P. Tessari |
Eben P. Tessari is the founder. In 2015, he founded Kiniksa Pharmaceuticals Ltd. and currently holds the title of Chief Operating Officer & Senior Vice President. Prior to founding Kiniksa Pharmaceuticals Ltd., Mr. Tessari held former positions at Civitas Therapeutics, Inc. as Director-Business & Corporate Development from 2013 to 2014, and at Synageva BioPharma Corp. as Senior Director & Head-Business Development from 2014 to 2015. Mr. Tessari's education history includes a graduate degree from Boston University and Suffolk University, as well as an undergraduate degree from Northeastern University. |
| Martina Struck |
Martina Struck is currently working as the Senior Vice President-Regulatory Affairs at Kiniksa Pharmaceuticals Ltd. She previously worked as the Head-Global Regulatory Affairs at Eisai, Inc. from 2006 to 2017. Dr. Struck holds a doctorate degree from the Swiss Federal Institute of Technology. |
| Mark Ragosa |
Mark Ragosa is currently the Chief Financial Officer & Director at Kiniksa Pharmaceuticals Corp. He also holds the position of Chief Financial Officer & Senior Vice President at Kiniksa Pharmaceuticals Ltd. Mr. Ragosa previously worked as the Director-Investor Relations at Ironwood Pharmaceuticals, Inc. and as a Vice President in the Equities Division at Goldman Sachs & Co. LLC. He completed his undergraduate degree at Bowdoin College. |
| Annalisa D’Andrea |
Annalisa D’Andrea occupies the position of Chief Scientific Officer of Kiniksa Pharmaceuticals Ltd.
Ms. D’Andrea previously occupied the position of Vice President & Global Head-Discovery at Roche Holding AG and Executive Director & Head-Discovery Biology at SRI International.
She received an undergraduate degree from the University of Siena and an undergraduate degree from the University of Florence. |
| Ross Moat |
Ross Moat is currently the Chief Commercial Officer & Senior Vice President at Kiniksa Pharmaceuticals Ltd. He previously worked as the General Manager at Synageva BioPharma Corp. and as the VP-EMEA Marketing & Commercial Operations at Novartis Gene Therapies, Inc. Mr. Moat completed his undergraduate degree at Middlesex University. |
| Arian Pano |
Arian Pano is Chief Development Officer & SVP at Kiniksa Pharmaceuticals Ltd. |
| Chad Morin |
Chad Morin is currently the Chief Compliance Officer & Vice President at Kiniksa Pharmaceuticals Ltd. He previously worked as the Head-Compliance at ARIAD Pharmaceuticals, Inc. and as the Chief Compliance Officer & Vice President at bluebird bio, Inc. Mr. Morin completed his undergraduate degree at F.W. Olin Graduate School of Business. |
| Mei Jang |
Mei Jang is currently working as the SVP-Technical Operations at Kiniksa Pharmaceuticals Ltd. Prior to this, Ms. Jang worked at Tesaro, Inc. as the Head-Biologics Downstream Process Development. Ms. Jang holds a doctorate degree from The Ohio State University. |
| Rasmus Holm-Jorgensen |
Founder of Kiniksa Pharmaceuticals Ltd., Rasmus Holm-Jorgensen presently is Chief Financial Officer of Acrivon Therapeutics, Inc. and Chief Strategy & Portfolio Officer at Kiniksa Pharmaceuticals Ltd.
He received a graduate degree from the University of Copenhagen. |
| Michael R. Megna |
Michael R. Megna is currently the Chief Accounting Officer & Vice President-Finance at Kiniksa Pharmaceuticals Ltd. He previously worked as the Chief Accounting Officer & Corporate Controller at BioSphere Medical, Inc. from 2004 to 2010. He also held the position of Senior Vice President-Finance & Accounting at LFB USA, Inc. Mr. Megna completed his undergraduate degree at Siena College. |
| Sanj K. Patel |
Sanj K. Patel is the founder of the Sarcoma Foundation of America (founded in 2015) and Kiniksa Pharmaceuticals Ltd. (founded in 2015). He is currently the Chief Executive Officer & Director at Kiniksa Pharmaceuticals Corp. In the past, he held positions such as President, Chief Executive Officer & Director at Synageva BioPharma Corp. (2008-2015), Independent Director at BioCryst Pharmaceuticals, Inc. (2015-2018), Independent Director at Intercept Pharmaceuticals, Inc. (2014-2015), Independent Director at Syros Pharmaceuticals, Inc. (2016-2018), and Head-Global Clinical Research Operations Council at Genzyme Corp. (1999-2008). Mr. Patel has an undergraduate degree from London South Bank University and a graduate degree from Ealing Hammersmith & West London College. |
| John F. Paolini |
John F. Paolini is currently the Chief Medical Officer & Senior Vice President at Kiniksa Pharmaceuticals Ltd. Prior to his current position, he held the role of Senior Director-Cardiovascular Disease at Merck & Co., Inc. and Head-Clinical Research-Cardiovascular at Pfizer Inc. He also worked as a Principal at Bayer HealthCare Pharmaceuticals, Inc. and served as the Chief Medical Officer at Cerenis Therapeutics, Inc. from 2011 to 2015. Additionally, he has experience as a Member at the University of Pennsylvania and as a Clinical Associate at Pennsylvania Hospital. Dr. Paolini completed his undergraduate studies at Tulane University (Louisiana) and obtained graduate and doctorate degrees from Duke University School of Medicine. |
| Melissa Manno |
Melissa Manno is currently the Chief Human Resources Officer & Senior VP at Kiniksa Pharmaceuticals Ltd. She previously worked as the Director-Human Resources at Synageva BioPharma Corp. from 2014 to 2015 and as the Partner-Global Human Resources Business at Alexion Pharmaceuticals, Inc. from 2015 to 2017. Ms. Manno completed her undergraduate degree at Keene State College. |
| Thomas R. Malley |
Thomas R. Malley is currently the Chairman at Project C.U.R.E., Inc. He is also an Independent Director at Kura Oncology, Inc., a Director at Benevolent Healthcare Foundation, an Independent Director at Kiniksa Pharmaceuticals Ltd., and an Independent Director at Kiniksa Pharmaceuticals Corp. Additionally, he serves as the President of Mossrock Capital LLC. In the past, Mr. Malley held positions as a Director at Cougar Biotechnology, Inc., a Director at Innovative Acquisitions Corp., a Board of Director at Craig Hospital, a Director at Janssen Oncology, Inc., an Independent Director at Puma Biotechnology, Inc., an Independent Director at OvaScience, Inc., and an Independent Director at Synageva BioPharma Corp. He also served as an Executive Vice President at Janus Henderson Investors US LLC and as a Portfolio Manager at Janus Henderson Global Life Sciences Fund. Mr. Malley obtained his undergraduate degree from Stanford University in 1991. |
| Richard S. Levy |
Richard S. Levy is currently serving as a Non-Executive Director at Gliknik, Inc. since 2014, an Independent Director at Kiniksa Pharmaceuticals Ltd. since 2019, an Independent Director at Madrigal Pharmaceuticals, Inc. since 2016, an Independent Director at Kodiak Sciences, Inc. since 2018, and an Independent Director at Protara Therapeutics, Inc. since 2019. Previously, he held positions as an Independent Director at Aquinox Pharmaceuticals, Inc. from 2017 to 2019, an Independent Director at Constellation Pharmaceuticals, Inc. from 2020 to 2021, a Director at ArTara Subsidiary, Inc. from 2019 to 2020, a Vice President-Biologic Therapies at Celgene Corp. from 2002 to 2003, the Chief Drug Development & Medical Officer and EVP at Incyte Corp. from 2003 to 2016, and a Vice President-Medical & Commercial Strategy at DuPont Pharmaceuticals Co. from 1997 to 2002. He also worked as an Assistant Professor at the David Geffen School of Medicine. Dr. Levy completed his undergraduate studies at Brown University and obtained doctorate degrees from the University of Pennsylvania and the Perelman School of Medicine. |
| Kimberly J. Popovits |
Kimberly J. Popovits is currently serving as an Independent Director at 10X Genomics, Inc. She is also a Director at the American Clinical Laboratory Association, the Personalized Medicine Coalition, the California Biomedical Innovation Alliance, Kiniksa Pharmaceuticals Corp., the California Life Sciences Association, Talis Biomedical Corp., Genomic Life, Inc., and The Coalition for 21st Century Medicine. Previously, she held the position of Chairman, President & Chief Executive Officer at Genomic Health, Inc. from 2012 to 2019. She was also the Vice Chairman at Nuvelo, Inc. from 2005 to 2009 and an Independent Director at ZS Pharma, Inc. in 2015. Additionally, she served as an Independent Director at MyoKardia, Inc. from 2017 to 2020. Ms. Popovits started her career at Genentech, Inc. in 1987, where she held the position of Senior Vice President-Marketing & Sales from 2001 to 2002. She also worked as a Division Manager at American Hospital Supply Corp. and American Critical Care Services, Inc. . She completed her undergraduate degree at Michigan State University. |
| G. Bradley Cole |
G. Bradley Cole is currently an Independent Director at Castle Biosciences, Inc. and Kiniksa Pharmaceuticals Ltd. He is also the Chief Financial Officer & Director at Genomic Life, Inc. and a Trustee at Biola University, Inc. (California). Previously, Mr. Cole held the position of Vice President-Finance & Business Development at Guidant Corp. from 1997 to 2004. He was also the Chief Financial Officer & Vice President-Finance at EndoVascular Technologies, Inc. from 1994 to 1997. In addition, he served as the General Manager-Precision Oncology at EXACT Sciences Corp. from 2019 to 2020 and as the Chief Operating Officer at Genomic Health, Inc. from 2013 to 2014. Prior to that, he was the Chief Financial Officer & Vice President-Finance at Applied Biosystems, Inc. from 1988 to 1994. Mr. Cole completed his undergraduate degree at Biola University, Inc. (California) and holds an MBA from San Jose State University. |
| Stephen R. Biggar |
Dr. Stephen R. Biggar is a Chairman at TScan Therapeutics, Inc., an Independent Director at Kiniksa Pharmaceuticals Ltd. and a Chairman at ACADIA Pharmaceuticals, Inc. He is on the Board of Directors at Kiniksa Pharmaceuticals Ltd. and Notch Therapeutics, Inc. Dr. Biggar was previously employed as an Independent Director by Synageva BioPharma Corp. and a Partner by Baker Bros. Advisors LP. He also served on the board at BioCryst Pharmaceuticals, Inc., Neurogene, Inc., Synageva BioPharma Corp. /Old/ and Vivelix Pharmaceuticals, Ltd. He received his undergraduate degree from Rochester Christian University and a doctorate degree from Stanford University. |
| Tracey L. McCain |
Tracey L. McCain is an Independent Director at Kiniksa Pharmaceuticals Ltd. since 2018 and at Blueprint Medicines Corp. since 2016. Previously, McCain served as an Independent Director at ImmunoGen, Inc. from 2021 to 2024. McCain was also the General Counsel at Genzyme Corp. from 1997 to 2016. Additionally, McCain worked as an Associate at Palmer & Dodge LLP and as the Senior Vice President & Head-Legal at Genzyme Therapeutics Ltd. in 2016. McCain completed an undergraduate degree at the University of Pennsylvania in 1989 and a graduate degree at Columbia Law School in 1992. |
| Barry D. Quart |
Dr. Barry D. Quart is a Chief Executive Officer & Director at Connect Biopharma Holdings Ltd. and an Independent Director at Kiniksa Pharmaceuticals Ltd. He is on the Board of Directors at Connect Biopharma Holdings Ltd., Kiniksa Pharmaceuticals Ltd., Kiniksa Pharmaceuticals Corp. and NeuroGenetic Pharmaceuticals, Inc. Dr. Quart was previously employed as a Chairman & Chief Executive Officer by Heron Therapeutics, Inc., an Independent Director by Synageva BioPharma Corp., a President, Chief Executive Officer & Director by Ardea Biosciences, Inc., a President by PS Pharmaceuticals, Inc., a President-Research & Development by Agouron Pharmaceuticals LLC, a Director, SVP-Global Research & Development by Pfizer (La Jolla), and a Senior VP-Pfizer Global Research & Development by Pfizer Inc. He also served on the board at Trimeris, Inc. He received his doctorate degree from The University of California, San Francisco. |
